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Abstract: Background: The aims of this narrative review were to examine up-to-date literature
in order to evaluate the effectiveness of arthrocentesis or injections with platelet-rich plasma in
temporomandibular affections and to compare them to arthrocentesis alone or with hyaluronic acid
(HA) or to hyaluronic acid injections. Methods: The search of international literature was made on the
PMC, PubMed and Cochrane databases, including all full-length text of studies on humans focused
on osteoarthritis and disc displacements and their treatment with platelet-rich plasma arthrocentesis
or injections. All design studies were included in the review and they were examined for three
different outcomes: pain, joint sound and mandibular motion. English papers were only selected.
Results: Even though the low number of studies in this field, arthrocentesis with platelet-rich
plasma and platelet-rich plasma injections in temporomandibular disorders’ management were
found to be effective in reducing pain and joint sound as well as in improving mandibular motion
in a maximum follow-up of 24 months. Conclusion: Comparison to arthrocentesis alone or to HA
use in arthrocentesis or by injections provided encouraging results in terms of the effectiveness of
platelet-rich plasma use.
Keywords: temporomandibular joint (TMJ); temporomandibular joint disorders (TMD); platelet-rich
plasma; arthrocentesis; injection; hyaluronic acid
1. Introduction
Temporomandibular joint disorders (TMDs) affect the jaw joints and related structures causing
internal derangement of joint space, bone alterations and degenerative pathologies. Frequent signs and
symptoms of TMDs are pain, joint noise, limited range of motion, impaired jaw function, deviation or
deflection upon mouth opening and closing or open locking [1,2].
Internal derangements of temporomandibular joint (TMJ) include disc displacements, with or
without reduction, often responsible for joint sounds, pain and discomfort in the TMJ area. Generally,
joint displacements are strictly related to the structure and cinematics of the TMJ and masticatory
system [3], however they can be also caused by peculiar anatomical morphology of the condyle, glenoid
fossa and articular eminence [4]. Furthermore, age, dentition and patterns of masticatory muscle
could be important factors in determining or maintaining temporomandibular joint dislocations [5].
Disc displacements occur when a disc is located outside of its normal position in the joint spaces.
The normal disc position means a 12 o’clock position of the posterior band and a 10 o’clock position of
the intermediate zone of the disc. The disc has a “bow tie” shape with a thin intermediate zone with
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the narrowest inter-bony distance. Displacement of the disc can present displacements in any direction,
but anterior disc displacement is most common. In dislocation with reduction, the posterior band of the
disc was located anteriorly to the condylar head in the closed position, but with a normal disc–condyle
relationship with the mouth opened by 1 inch. In non-reducing displacement, the posterior band was
positioned anteriorly to the condyle both with the mouth closed and opened 1 inch [6].
Disc displacement with or without reduction of the TMJ is an intracapsular dysfunction that leads
to degenerative changes in the disc and articular surface [7].
Osteoarthritis (OA) of the TMJ is characterized by degenerative alterations of bone, cartilage and
supporting tissues causing pain, stiffness and loss of function [8]. It is more common in the female
than the male and it has a degenerative pattern leading to bone erosion, sclerosis and bony alterations
such as osteophytes and flattening of condyle surface [9]. In most of cases, limitations in motion occurs
and patients are not able to effectively chew or achieve a normal mouth opening without pain.
Different treatments of OA and disc displacement are reported in literature and performed in
clinical practice and they include conservative therapy such as painkillers, resting the jaw, splints
and physiotherapy and surgical interventions as arthrocentesis, disc repositioning or discectomy in
non-responder patients.
Treatment outcomes of arthrocentesis of the TMJ are improvements of mouth opening and pain
relief during the mandibular motion with consequent enhancing of it [8,10].
Even though literature reports the possibility to perform solely arthrocentesis to reach these
outcomes [8,11], further studies have been carried out to better investigate the effectiveness of
different techniques to perform arthrocentesis by using growing factors, autologous solutions or
alternative materials; the materials most used are platelet-rich plasma (PRP) and hyaluronic acid (HA)
in arthrocentesis or by injection.
Platelet-rich plasma is produced by centrifuging heparinized whole autologous blood for 15 min
and separating the platelets from the other blood components. Later, the platelets are diluted with
normal saline solution to obtain the optimal concentration. This represents an emerging regenerative
therapy for injuries in the orthopaedic field with encouraging results showing anti-inflammatory,
analgesic and antibacterial properties [12–14].
PRP has recently been considered as an orthobiological adjuvant treatment. It also restores
intra-articular hyaluronic acid, increases glycosaminoglycan chondrocyte synthesis, balances joint
angiogenesis, and provides a scaffold for stem cells migration. Basic scientific studies have indicated
that PRP stimulates cell proliferation and the production of cartilage matrix by chondrocytes and
bone marrow-derived mesenchymal stromal cells and increases the production of hyaluronic acid by
synoviocytes [15].
HA is a high-molecular-weight glycosaminoglican naturally present in synovial fluid and
participating in joint lubrification. Injections of HA have been widely used in the treatment of TMDs
in single-dose or repeated or associated with other procedures, such as arthrocentesis or arthroscopy,
and several published studies show positive and encouraging results in improvement of mouth
opening and pain relief [1,16–18].
Despite the extensive literature on the use of PRP in the treatment of articular disorders in
orthopedics, its application in TMDs is quite unexplored, and therefore this narrative review should
deeper investigate PRP effectiveness in TMDs treatment.
The primary aim of this review is to assess the effectiveness of PRP in arthrocentesis or by
injections in terms of reducing pain, joint sounds and improving mandibular motion in patients
affected by osteoarthritis or internal derangement of the TMJ.
The secondary aim is to compare the effectiveness of PRP in arthrocentesis to HA in arthrocentesis
or injected to arthrocentesis alone in affected patients.
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2. Research Methods
The methodological approach of this work is a narrative review in order to summarize the
main findings of literature, to better outline and to improve knowledge in the field of interest [19].
Specifically, we used concepts proposed by Egger et al. to perform narrative review of the literature
according to the following steps (Table 1) [20].
Table 1. Methodological approach to review.
Step General Activities Specific Activities
I Formation of working group
One maxillofacial surgeon expert in arthrocentesis of TMJ,
as clinical and methodological operator
One medical doctor expert in head and neck anathomy
and PRP, as clinical and methodological operator
One researcher expert in TMJ disorders,
as methodological operator
II Formulation of thereview questions
Evaluation of the state of art inTMJ osteoarthritis and
arthrocentesis. Analysis of main effects of osteoarthritis in
TMJ and its treatment
III Identification of relevant studieson PubMed, PMC, Cochrane
1. Identification of keywords in the field of interest
2. Use of Boolean operators (AND; OR; NOT)
3. Advanced search (Table 2 for serach strategy)
4. Inclusion criteria: papers published from 1950 to 2018;
language: english; all types of full text articles
5. Elimination of duplicate
6. Manual search through the references in selected articles
IV Anaysis and presentation Data extrapolated from all revised studies were shownin tables in form of narrative review
Step I: formation of a working group composed of three members. Each of them performed as methodological
reviewer and two of them also as clinical expert. Step II: Formulation of review questions derived from up-to-date
knowledge on TMJ osteoarthritis, treatment strategies and outcomes. Crucial step to effectively build a search
strategy. Step III: using keywords concerning the topic to perform search in databases (PubMed, PMC, Cochrane).
Boolean operators were all applied to search in order to establish proper relationships among concepts (Table 2).
Step IV: analysis and presentation of all extrapolated data were collocated in table in form of narrative review and
explanation in the results section of this paper.
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Table 2. Search strategy.
Search Database
((“platelet-rich plasma”[MeSH Terms] OR (“platelet-rich”[All Fields] AND “plasma”[All Fields]) OR “platelet-rich plasma”[All Fields] OR (“platelet”[All
Fields] AND “rich”[All Fields] AND “plasma”[All Fields]) OR “platelet rich plasma”[All Fields]) AND (“temporomandibular joint”[MeSH Terms] OR
(“temporomandibular”[All Fields] AND “joint”[All Fields]) OR “temporomandibular joint”[All Fields] OR “tmj”[All Fields])) NOT (extraction[All Fields]
AND (“tooth”[MeSH Terms] OR “tooth”[All Fields] OR “teeth”[All Fields]))
PMC
(((“joint diseases”[MeSH Terms] OR (“joint”[All Fields] AND “diseases”[All Fields]) OR “joint diseases”[All Fields] OR “arthrosis”[All Fields]) AND
(“temporomandibular joint”[MeSH Terms] OR (“temporomandibular”[All Fields] AND “joint”[All Fields]) OR “temporomandibular joint”[All Fields] OR
“tmj”[All Fields])) AND ((“arthritis”[MeSH Terms] OR “arthritis”[All Fields]) AND (“temporomandibular joint”[MeSH Terms] OR
(“temporomandibular”[All Fields] AND “joint”[All Fields]) OR “temporomandibular joint”[All Fields] OR “tmj”[All Fields]))) AND (“platelet-rich
plasma”[MeSH Terms] OR (“platelet-rich”[All Fields] AND “plasma”[All Fields]) OR “platelet-rich plasma”[All Fields] OR (“platelet”[All Fields] AND
“rich”[All Fields] AND “plasma”[All Fields]) OR “platelet rich plasma”[All Fields])
PMC
((((“temporomandibular joint”[MeSH Terms] OR (“temporomandibular”[All Fields] AND “joint”[All Fields]) OR “temporomandibular joint”[All Fields])
AND (“osteoarthritis”[MeSH Terms] OR “osteoarthritis”[All Fields])) AND (“osteoarthritis”[MeSH Terms] OR “osteoarthritis”[All Fields] OR
“osteoarthrosis”[All Fields])) AND (disk[All Fields] AND (“displacement (psychology)”[MeSH Terms] OR (“displacement”[All Fields] AND
“(psychology)”[All Fields]) OR “displacement (psychology)”[All Fields] OR “displacement”[All Fields]))) AND (“platelet-rich plasma”[MeSH Terms] OR
(“platelet-rich”[All Fields] AND “plasma”[All Fields]) OR “platelet-rich plasma”[All Fields] OR (“platelet”[All Fields] AND “rich”[All Fields] AND
“plasma”[All Fields]) OR “platelet rich plasma”[All Fields])
PMC
(((“joint diseases”[MeSH Terms] OR (“joint”[All Fields] AND “diseases”[All Fields]) OR “joint diseases”[All Fields] OR “arthrosis”[All Fields]) AND
(“temporomandibular joint”[MeSH Terms] OR (“temporomandibular”[All Fields] AND “joint”[All Fields]) OR “temporomandibular joint”[All Fields] OR
“tmj”[All Fields])) AND ((“arthritis”[MeSH Terms] OR “arthritis”[All Fields]) AND (“temporomandibular joint”[MeSH Terms] OR
(“temporomandibular”[All Fields] AND “joint”[All Fields]) OR “temporomandibular joint”[All Fields] OR “tmj”[All Fields]))) AND (“platelet-rich
plasma”[MeSH Terms] OR (“platelet-rich”[All Fields] AND “plasma”[All Fields]) OR “platelet-rich plasma”[All Fields] OR (“platelet”[All Fields] AND
“rich”[All Fields] AND “plasma”[All Fields]) OR “platelet rich plasma”[All Fields])
PubMed
((Therapy/Broad[filter] AND ((“platelet-rich plasma”[MeSH Terms] OR (“platelet-rich”[All Fields] AND “plasma”[All Fields]) OR “platelet-rich
plasma”[All Fields] OR (“platelet”[All Fields] AND “rich”[All Fields] AND “plasma”[All Fields]) OR “platelet rich plasma”[All Fields]) AND
maxillofacial[All Fields])) NOT extraction[All Fields]) AND ((“osteonecrosis”[MeSH Terms] OR “osteonecrosis”[All Fields]) AND (“jaw”[MeSH Terms] OR
“jaw”[All Fields]))
PubMed
(((“platelet-rich plasma”[MeSH Terms] OR (“platelet-rich”[All Fields] AND “plasma”[All Fields]) OR “platelet-rich plasma”[All Fields] OR (“platelet”[All
Fields] AND “rich”[All Fields] AND “plasma”[All Fields]) OR “platelet rich plasma”[All Fields]) AND (“temporomandibular joint disorders”[MeSH Terms]
OR (“temporomandibular”[All Fields] AND “joint”[All Fields] AND “disorders”[All Fields]) OR “temporomandibular joint disorders”[All Fields] OR
(“tmj”[All Fields] AND “disorders”[All Fields]) OR “tmj disorders”[All Fields])) AND maxillofacial[All Fields]) NOT (extraction[All Fields] AND
(“tooth”[MeSH Terms] OR “tooth”[All Fields] OR “teeth”[All Fields]))
PubMed
((“temporomandibular joint”[MeSH Terms] OR (“temporomandibular”[All Fields] AND “joint”[All Fields]) OR “temporomandibular joint”[All Fields] OR
“tmj”[All Fields]) AND (“Pharmacol Res Perspect”[Journal] OR “prp”[All Fields])) AND (“surgery”[Subheading] OR “surgery”[All Fields] OR “surgical
procedures, operative”[MeSH Terms] OR (“surgical”[All Fields] AND “procedures”[All Fields] AND “operative”[All Fields]) OR “operative surgical
procedures”[All Fields] OR “surgery”[All Fields] OR “general surgery”[MeSH Terms] OR (“general”[All Fields] AND “surgery”[All Fields]) OR “general
surgery”[All Fields])
PubMed
tmj, arthrocentesis, prp, osteoarthritis:ti, ab, kw (Word variations have been searched) Cochrane
Inclusion criteria were: all types of articles, related only to humans, articles exclusively related to TMJ published form January 1950 to May 2018. Exclusion criteria were: articles for which
full text was not available, were not in English, or were grey literature. Duplicate articles were eliminated and, from the articles retrieved in the first round of search, additional references
were identified by a manual search among the cited references. Process of literature selection was reported following the PRISMA (Preferred Reporting Items for Systematic Reviews and
Meta-analyses statement guidelines.
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Ten papers included were subsequently divided into different subgroups of interest based on our
outcomes and study variables in order to investigate in depth the particular contribution of each article.
We chose specific keywords for each topic in order to highlight our outcomes in the papers (Table 3).
Table 3. Advanced and specific search.
Subgroups Outcome Topic Specific KeywordsSearched in Papers
1 Signs andsymptoms improvement
Pain, Mandibular motion,
Joint sounds
“Pain”; “Maximum mouth
opening”; “VAS scale”;
“Joint sound”; “Chewing”; “Stiff”,
“Mandibular mobility”
2
Effectiveness of
PRP-associated
arthrocentesis
Arthrocentesis alone, Arthrocentesis
hyaluronic acid (HA) associated,
Arthrocentesis PRP associated,
Arthrocentesis associated with
other biomaterials or drugs
“Arthrocentesis”;
“Platelet-rich-plasma”;
“Hyaluronic acid”,
“Corticosteroid”, “Growing factors”
First, in order to examine signs and symptoms of TMJ OA and internal derangements, we based
our evaluation on all papers that reported an evaluation and outcome. Considering that VAS scale,
ability in mouth opening and joint sound have been used as parameters in all studies, we considered
them as rating parameters. Second, to investigate the treatment proposed, we focused attention on all
works proposing PRP arthrocentesis or PRP injection or arthrocentesis in TMJ. Conservative therapies
in OA and internal derangements, such as painkillers or dental splints, were not taken into account
because not objective of this review, except where combined with arthrocentesis or PRP injections.
3. Results
Literature screening led to the evaluation of 10 full-length articles (Figure 1).
Figure 1. Literature selection process.
Different kinds of studies were taken into consideration, such as randomized controlled trials
(RCT), randomized prospective studies, observational studies, clinical studies and retrospective
cohort studies.
Table below shows characteristics of studies itemised by intervention, sample size, studies’ design
and outcomes measurement (Table 4).
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Table 4. Results. SG: Sample Group; CG: Control Group; RDC/TMD: Research Diagnostic Criteria for Temporomandibular Disorders; DC/TMD: Research Diagnostic
Criteria for Temporomandibular Disorders; CBCT: Cone Beam Computed Tomography.
Studies Affection Study Design Diagnostic Criteria Intervention Sample Endpoint Outcomes Results
Gicomello
et al., 2014
Osteoarthritis,
Non-reducing
Anterior
Displacement
Observational
Study
Ortopantomography
and magnetic
resonance
imaging (MRI)
2 PRP injections
at 30 days
SG, N = 13,
Mean age: 47.64 6 months
Pain (visual analogue
scale, VAS); Mandibular
opening (MMO)
Pain improvement from 7.69 ± 1.9 to
0.23 ± 0.63 (*). MMO improvement
from 30.15 ± 4.44 to 39.54 ± 4.55 (*)
Hanci
et al., 2014
Reducing Anterior
Displacement
Randomized
Controlled Trial
(RCT)
MRI
SG: 1 singole PRP
Injection, CG:
Arthrocentesis
SG, N = 10,
Mean age: 27.2.
CG, N = 10,
Mean age: 25.4
6 months
Pain (VAS); Minimal
Interincisal Opening
(MIO); Joint Sound
(Number of Joints affected)
Pain improvement: SG from
6.69 ± 2.21 to 0.07 ± 0.27. CG: from
6.52 ± 2.29 to 2.76 ± 1.48 (*). MIO
improvement: SG from 32 ± 8.53 to
39.7 ± 10.39. CG from 30.2 ± 9.41 to
36.3 ± 5.51 (**). Joint Sound
improvement: SG: from 12 to 2. CG
from 12 to 5 (*)
Pihut et al., 2014 Temporomandibulardisfunctions
Clinical Study
(Preliminary)
Clinical (RDC/TMD
questionnaire) PRP injection
SG, N = 10,
Mean age: 37.6 6 weeks
Pain (VAS); Mandibular
Motion (MM);
Joint Sound
(Number of patients)
Pain improvement: from 6.5 to 0.6
(*); MM decrease to 1 (not clear);
Joint Sound: from 4 to 1
Hegab
et al., 2015 Osteoarthritis RCT Radiography or MRI
SG: 3 PRP Injections,
CG: 3 HA Injections
SG: N = 25,
Mean age: 39.
CG: N = 25,
Mean age: 38.2
12 months
Pain (VAS); Mouth
Voluntary Opening
(MVMO); Joint Sound
(Number of Joints
affected)
Pain improvement: SG from
7.36 ± 1.14 to 0.4 ± 0.763. CG: from
6.96 ± 1.24 to 1.64 ± 1.35 (*). MVMO
improvement: SG from 33.88 ± 3.08
to 41.56 ± 2.31. CG from
32.40 ± 2.72 to 39.28 ± 2.80 (*). Joint
Sound improvement: SG > CG at 1
month, SG = CG at 12 months (**)
Al-Delayme
et al., 2016
Non-reducing
Anterior
Displacement
Observational
Study
Bilateral palpation and
measurement of
mouth opening
2 PRP injections SG: N = 44,Mean age: 36.6 6 months
Pain (VAS); Maximum
Mouth Opening (MMO);
Joint Sound (VAS)
Pain improvement from 33.5 ± 22.4
to 18.3 ± 17.9 (*). MMO
improvement from 26.4 ± 11.3 to
41.5 ± 8.65 (*). Joint Sound
imprvement from 79.3 ± 12.8 to
2.9 ± 15 (*)
Kiliç et al., 2015 Osteoarthritis RCT Clinical (DC/TMDs)and CBCT
SG: Arthrocentesis +
PRP 4 monthly PRP
Injections, CG:
Arthrocentesis
SG: N = 18, 32
Joints, Mean
age: 32.22. CG:
N = 12, 15 Joints,
Mean age: 35.08
12 months
Pain (VAS); Maximum
Mouth Opening (MMO)
(VAS); Joint Sound (VAS)
Pain improvement: SG from
5.70 ± 1.35 to 1.02 ± 1.88. CG: from
6.83 ± 2.28 to 2.43 ± 4.08 (*). MMO
improvement: SG: from 38.72 ± 7.84
to 38.39 ± 8.02 (**). Joint Sound: SG
from 5.48 ± 3.46 to 0.70 ± 0.85. CG
from 5.45 ± 3.27 to 0.75 ± 1.42 (*)
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Table 4. Cont.
Studies Affection Study Design Diagnostic Criteria Intervention Sample Endpoint Outcomes Results
Kiliç et al., 2016 Osteoarthritis RCT Clinical (DC/TMDs)and CBCT
SG: Artrocentesis+PRP
and 4 PRP Injections.
CG: 1 singole
Arthrocentesis + HA
SG: N = 18, 32
Joints, Mean
age: 32.22. CG:
N = 13, 17 Joints,
Mean age: 28.08
12 months
Pain (VAS); Maximum
Mouth Opening (MMO)
(VAS); Joint Sound (VAS)
Pain improvement: SG from
5.70 ± 1.35 to 1.02 ± 1.88. CG: from
5.71 ± 2.54 to 0.54 ± 0.87 (*). MMO
imrovement: SG from 38.72 ± 7.84 to
38.39 ± 8.02. CG from 44.23 ± 8.14
to 43.77 ± 6.39 (*). Joint Sound: SG
from 5.48 ± 3.46 to 0.70 ± 0.85. CG
from 5.81 ± 3.16 to 1.81 ± 3.04 (*).
Fernandez-Ferro
et al., 2017
Osteoarthritis,
Reducing or
Non-reducing disc
displacement
Randomized
Prospective
Study
MRI SG: PRP Injection; CG:HA Injection
SG: N = 50,
Mean age: 38.4.
CG:N = 50,
Mean age: 33.2
18 months Pain (VAS); MouthOpening (MO)
Pain improvement: SG from
8.35 ± 0.90 to 1.55 ± 1.90. CG from
8.14 ± 0.60 to 2.20 ± 1.43 (*). MO
improvement: SG from 27.74 ± 4.65
to 37.23 ± 4.94. CG from
27.92 ± 5.08 to 36.54 ± 5.78 (**)
Yang et al., 2017 Non-reducing discdisplacement
Retrospective
Cohort Study
Clinical (DC/TMDs)
and MRI
SG: LPCGF Injection +
Centric Relation
Occlusal Splint (Cros)
SG: N = 29,
Mean age: 39.55 24 monts
Pain (VAS); Joint Sound
(Number of joints
affetcted)
Pain improvement from 4.72 ± 2.58
to 1.10 ± 1.72. Joint Sound
improvement from 36 to 10 (*).
Lin et al., 2018 Osteoarthritis RetrospectiveStudy
Clinical (DC/TMDs)
and CBCT
SG: Arthrocentesis +
PRP: CG: PRP Injection
SG: N = 30,
Mean age: 42.73;
CG: N = 60,
Mean age: 38.73
12 months
Pain (VAS); Range
motion (>6 mm); Mouth
Assisted Opening (MAO);
Joint Crepitus Sound
(Number of patients)
Pain improvement: SG = CG no
improvement. Range Motion: SG
from 47% to 0%, CG from 20% to 2%
(*). MAO: SG and CG no
improvementJoint crepitus sound:
SG from 100% to 47% (**). SG vs. CG:
differences not
statistically significant.
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In four studies (Hegab et al., Kiliç et al., 2015 and 2016 and Lin et al.) out of 10 osteoarthritis was
the only affect tested; however in one work [21] (Giacomello et al.), authors evaluated also anterior disc
displacement without reduction. Fernandez-Ferro evaluated both osteoarthritis an disc displacement
with or without reduction [22]. Hanci et al. recruited a sample suffering from disc displacement
with reduction [10], Pihut and al. evaluated a sample affected by general temporomandibular
disfunctions [23], and Yang et al. and Al-Delayme et al. evaluated non-reducing disc displacement
samples [2,24].
One study out of 10 compared PRP injections to arthrocentesis [10] (Hanci et al.), two studies
out of 10 compared PRP injections to HA injections [15,22] (Hegab et al., Frenandez-Ferro et al.).
Three studies tested different doses of PRP injections without a control group (Giacomello et al.,
Pihut et al., Al-Delayme et al.,) and Yang et al. tested LPCGF (Liquid Phase Concentrated Growth
Factor) injection combined with centric relation occlusal splint without comparison [2,21,23,24]. In both
studies of Kiliç et al. (2015, 2016) PRP and arthrocentesis and PRP injection was compared with
arthrocentesis alone (2015) and with HA arthocentesis [8,9]. In Lin et al. PRP arthrocentesis was
compared with PRP injection [25].
3.1. Outcome of Pain Improvement
Pain was measured by VAS (visual analogue scale) in all works evaluated. Statistically significant
results in terms of pain improvement were highlighted in all works examined, except in Lin et al. [25].
Intra-group and inter-groups differences were noticed in all works where a control group was
involved. In those studies where control groups were not present, statistical differences were noted
between the baseline and the end of follow-up in the study group.
In Lin’s work, arthrocentesis plus PRP was compared to PRP injection in osteoarthritis and the
two groups did not show statistically significant differences in TMJ arthralgia [25]. Results of VAS
scores from all studies were found to be similar in values, except in Fernandez-Ferro et al. where a
slighter improvement was noticed, probably due to the larger sample tested [22].
Pain seems to improve when PRP is used, both by injections combined with arthrocentesis.
Furthermore, PRP injections were found to be more effective than HA injections (Hegab et al.,
Fernandez-Ferro et al.) [15,22].
3.2. Outcome of Joint Sound
In two studies joint sound was not evaluated (Giacomello et al. and Fernandez-Ferro et al.) [21,
22]. In three studies the joint sound was evaluated using VAS scale (Kiliç et al. 2015, 2016 and
Al-Delayme) [2,8,9], in three other studies it was calculated on joints affected by sound or crepitus
(Hanci et al., Hegab et al., Yang et al.) [10,15,24], and in another two number of patients reporting
sound was scored (Pihut et al., Lin et al.) [23,25].
In all of the works analysed joint sound was found to improve during follow up. In Hegab et al.
and in Pihut et al. results were not statistically significant, nevertheless an improvement was
noticed [15,23]. In particular, Hegab et al. reported improvements of joint sound when treated
with PRP injection compared to HA injection at 1 month of follow-up, however this improvement
became equal at 12 months follow-up [15].
In both studies carried out by Kiliç et al. statistically significant inter-groups resulting in
decreasing of joint sound were reported [8,9]. Hanci et al. showed also statistical differences between
two compared groups, as well as in Yang et al. and in Al-Delayme where statistical differences in
outcome were reported comparing baseline to end of follow-up [2,10,24].
In Lin et al. at 1 month and at 12 months statistically significant improvement of joint crepitus
sound was detected in patients treated by arthrocentesis and PRP. However, authors reported no
statistical differences until 12 months between two groups (arthrocentesis and PRP compared to PRP
injections) demonstrating a similar improvement of joint crepitus sound in both groups [25].
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3.3. Mandibular Motion Outcome
Different definitions of this outcome were reported by authors, for example mandibular opening,
mandibular motion, mouth voluntary opening and maximum mouth opening, minimal interincisal
opening, range motion. We generally assumed all of these as mandibular motion.
In all studies, except Yang et al., mandibular motion was considered and tested at baseline and at
the end of follow-up; furthermore, comparison between groups was carried out where a control group
was present [24].
In Giacomello et al. (2 PRP Injections) differences in mandibular opening between pre-injection
and post-injection were statistically significant [21].
Hanci et al. (PRP injection vs. arthrocentesis) investigated minimal interincisal opening founding
no statistically significant differences between study and control group [10].
Pihut et al. (PRP injection) reported a decrease of mandibular motion but the results are not
clearly explained [23].
Results in mandibular voluntary opening in Hegab et al. (PRP injections vs. HA injections) were
found to be statistically different between two groups [15]. In Kiliç et al. (2015) (PRP arthrocentesis vs.
arthrocentesis) results in maximum mandibular opening were not statistically different in two groups
whereas in the work of 2016 (PRP arthrocentesis vs. HA arthrocentesis) statistical differences were
noticed between study and control group [8,9]. Fernandez- Ferro et al. (PRP injection vs. HA injection)
did not find differences with statistical relevance between the two groups in testing mouth opening
before intervention and at the end of follow-up [22].
In Al-Delayme et al. (PRP injections), statistical differences between baseline and end of follow-up
were noticed [2].
Lin et al. (PRP arthrocentesis vs. PRP injections) showed a statistical significant improvement
in both groups after interventions (range motion higher than 6 mm), however no differences were
noticed in terms of mouth-assisted opening [25].
Yang et al. did not evaluate range motion outcome [24].
3.4. Risk of Bias Assessment
Selected studies differ from each other due to heterogeneity of sample size and TMJ affections
tested. The mean age of patients is ranged between 25.4 and 47.64 years.
Only four studies were RCT (Hanci et al., Hegab et al., Kiliç et al 2015 and 2016) [8–10,15] and one
was randomized prospective study (Fernandez-Ferro et al.) [22]. In three studies allocation concealment
and randomization technique were clearly explained (Kiliç et al. 2016, Fernandez-Ferro et al. and
Hegab et al.) [8,15,22].
Three studies did not have control group for comparisons (Giacomello et al., Pihut et al.,
Al-Delayme et al.) [2,21,23].
Two studies lacked outcomes on joint sound (Giacomello et al., Fernandez-Ferro et al.) [21,22].
All studies were considered at low risk of bias for selective reporting.
4. Discussion
The weak point of this work is lack of studies and their heterogeneity. Risk of bias assessment
clearly shows this weakness; however, the core aim of this review was to assess the effectiveness
of PRP use in TMJ affections, thus we focused our attention on all studies responding to this
topic. Literature does not provide a large spectrum of studies to perform a systematic review with
subsequent meta-analysis.
Because of limited literature, an open search strategy was performed in order to include a larger
number of studies. This methodological decision, however, led to difficulties in evaluating samples’
baseline conditions and outcomes.
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The first significant limitation in this work was the diagnostic criterium used in each study, some
study included OA patients, others considered also patients suffering from anterior disc displacement
with or without reduction. This meant heterogeneity in sample evaluated and subsequent difficulties
in comparing results of effectiveness of different therapeutic strategies. A further restriction we ran
into were the different ways to perform TMDs diagnosis in each study. Some studies used clinical
diagnosis, others magnetic resonance imaging (MRI) and others CBCT. Studies that performed only a
clinical evaluation might be considered critical in diagnosis strategy as instrumental assessment are
recommended in literature [26].
A further crucial point to take into account in evaluating bias are different ways used to prepare
PRP solutions in the studies analysed. Fernandez-Ferro et al. and Kiliç et al. (2015 and 2016) followed
the protocol proposed by Anitua et al. [27]. Lin et al. and Yang et al. followed Saccos’s protocol for PRP
preparation and management [28]. Giacomello et al. proposed to use PRGF-Endoret (plasma rich in
growth factors) with CaCl added and Al-Delayme et al. also added CaCl to PRP solution extracted [29].
Other authors proposed their own protocols for preparation, centrifugation and extraction of PRP
as well as times of administration. These differences did not allow for making considerations based
on standardised procedures and, therefore, the outcomes’ evaluation might be influenced. Moreover
the characterization of PRP contents in each solution used in different studies analysed represented a
critical point when we made comparisons in the effectiveness of PRP injections and PRP combined
with arthrocentesis. Patients’ characteristics from which PRP was extracted and its preparation were
not well specified in studies and literature that shows differences in effectiveness of PRP based on
blood properties and contents [30]. For example concentration of specific growth factors, or cytokines
could affect the PRP properties and it is an aspect to evaluate when comparing studies [31].
A further point is the injection technique of PRP; each author described his own surgical approach
in administration of PRP. This aspect could be an additional critical issue in this review, even though,
in our opinion, this does not represent a great matter of concern because PRP solution reached the
intracapsular area in all cases.
In some studies, pain outcome was reported as TMJ arthralgia and other authors referred to
myofascial pain; we assumed both conditions as pain outcome in order to evaluate changes after
different therapies. The same approach was taken in evaluating mandibular motion because of
differences within outcomes in studies. We considered as mandibular motion all outcomes proposed,
such as mandibular opening (Giacomello et al.) [21], minimal interincisal opening (Hanci et al.) [10],
mandibular motion (Pihut et al.) [23], mouth voluntary opening (Hegab et al.) [15], maximum mouth
opening (Al-Delayme et al., Kiliç et al. 2015, 2016) [2,8,9], mouth opening (Fernandez-Ferro et al.) [22]
and range motion and mouth-assisted opening (Lin et al.) [25]. With regards to interventions, we
considered both injections of PRP and arthrocentesis with PRP not taking into account different
methods to inject PRP or to perform arthrocentesis due to a shortage of studies available. Published
data about PRP treatment for TMDs with which to establish application protocols are limited; however,
authors did not report complications in using different techniques or composition of solutions [32,33].
Follow-up duration varied among studies and this aspect made it impossible to directly
compare them.
Taking into account these limitations, based on recent literature findings and considerations about
PRP use and TMDs’ etiopathogenetic behaviours, comparisons and evaluations of outcomes among
all studies were performed, albeit at the expense of the methodological rigour.
In recent years, literature demonstrated that excessive metabolic reactions occur in TMDs
conditions and, therefore, changes in microenvironment around cartilage and bone with subsequent
damage appear [34]. Consequently pain and dysfunction in mandibular motion are related to an
increase of pressure in the joint and to the great amount of cytokines in synovial liquid [22]. Literature
suggests that PRP injection could improve these conditions, not only thanks to the expansion of the
joint cavity, but also because of growth factors which can restore disc, capsule and retrodiscal pad
and inhibit pro-inflammatory cytokines [35–37]. According to these findings, results of this review
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show clear improvement when PRP injections were performed, regardless of injection modalities or
periodicity. This occurs even when PRP injections are compared with HA injections (Hegab et al.).
In particular, Hegab et al. show HA injections are comparable in effects to PRP injections in a medium
follow-up; however, PRP allows better performances at the long-term follow-up without recurrence
of pain and joint sound at 12 months [15]. Al-Delayme reported the effectiveness of PRP injection
as primary treatment of non-reducing disk displacement, however assumed this to be an optimal
duration of therapy 6 months, after which it might be considerable an additional injection [2]. Results
of efficacy and modes of action of PRP use in TMDs are rare, and hence knowledge resulting from
orthopaedic research: the mechanism for leading the patients to better condition with PRP injection
remains obscure, nevertheless most authors report that PRP is a natural source of autologous growth
factors and it could improve cartilage repairs [38,39]. Authors tested PRP and HA in the treatment of
knee joint osteoarthritis and results were better in the group of patients who received PRP injections
after a 3 and 6 months follow-up [40].
The inflammatory modulating capability of PRP was found to be crucial in reducing signs and
symptoms of TMDs and this aspect seemed to play a key role in results of this review. In all studies
where PRP was used, improvement of outcomes was detected. However debated results are presented
in Kiliç (2016) regarding the effectiveness of PRP compared to HA in arthrocentesis [8]. Both biological
factors resulted in significant clinical improvements of all outcomes, and it can indeed be extrapolated
that PRP is perhaps inferior to HA, because results from four additional PRP injections seemed to be not
better than one session of HA injection. There are no strong scientific data about temporomandibular
joints to accept or reject this assumption, and other joints were more deeply investigated in orthopaedic
field, despite with controversial results. Raeissadat et al. compared the efficacy of two PRP injections
and three HA injections for treatment of knee osteoarthritis and the results indicated that two PRP
injections were more efficacious than three HA injections in reducing knee symptoms [41]. With respect
to TMDs, Fernandez-Ferro et al. reported how the infiltration of PRGF after an arthroscopy procedure
shows better results for both pain and mouth opening with respect to HA. However no statistical
difference was reported in the mouth opening outcome.
In view of this, it is difficult to gain results of PRP and HA comparisons, and there is no strong
evidence in literature. It should certainly be considered that HA is more readily available, it does
not require any invasive preparation procedure involving patients, and it is characterized by good
tolerability and therapeutic effects (pain relief) [42,43]. Therefore stronger evidence might be required
in order to chart the best course of treatment, also taking into account the invasiveness of preparation
procedures and patients needing. Based on results of this narrative review, where pain relief is
needed, PRP injections should be preferred to HA injections. The same therapeutic strategy could
be undertaken when mandibular motion improvement is required, even if, at 18 months follow-up,
results about this outcome seem to be overlapping both with PRP and HA injections in the case of OA
and disc displacements (Fernandez-Ferro et al.) [22]. Furthermore, where joint sound improvement
is needed, PRP seems to be preferable to HA (Hegab et al.) [15]; however, also with reference to this
outcome, the results become the same at the end of the follow-up. However, it might be considered
whether joint sound improvement is a primary outcome desired or it is secondary to pain relief and
mandibular motion. Patients actually first require a decrease in pain and enhancement of mandibular
cinematics, and therefore joint sound improvement.
In light of these findings and taking into account the limited and heterogeneous studies in
literature, we might assume that the best therapeutic choice among PRP and HA should be driven by
a patient’s needs, their systemic conditions, and the outcomes to be reached. Until further studies and
extended follow-ups are undertaken, it could be advisable to prefer PRP arthrocentesis or injections;
however, sometimes it can be difficult to obtain PRP and, therefore, HA could be the best choice.
Comparing PRP injections or PRP combined with arthrocentesis to arthrocentesis alone, the results
were more encouraging and clear. Statistically significant values were highlighted in Kiliç et al.
(2015) [9] where patients who underwent four PRP injections show greater masticatory efficiency
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than the patients without PRP injections (only arthrocentesis), and CBCT findings confirmed two-fold
better reparative remodelling in OA [9]. An interesting consideration could be made about Lin et al.,
where PRP injections and PRP arthrocentesis were compared, showing reparative remodeling in both
treatments. This study reported also that an arthrocentesis prior to one single PRP injection could lead
to more satisfactory outcomes, where TMJ OA is accompanied by clinical symptoms [25].
In accordance with the literature, PRP was found to have relevant antinflammatory and
regenerative properties, capability of modulating synovial cell biology, increasing HA concentration
and stabilizing angiogenesis [44] and these peculiar features probably provided PRP with higher
efficacy also in the treatment of TMDs compared to arthrocentesis and HA injections.
PRP use, by injection or combined with arthrocentesis, in the treatment of TMDs was found to
be more effective than arthrocentesis alone or combined with HA. This could be attributable to the
inflammatory modulating capability of PRP in TMJ. More studies, especially RCTs, are required to fix
these results.
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